Raptor is launching an ultra-Orphan drug it has shown is non-inferior to a cheaper alternative without having payers on board with the $250,000 price. It is banking on quality of life gains from better compliance.
Shire is paying collaborators to propose their best ideas for innovation in rare diseases, and is applying a similar open mind in its investment partnership with Atlas Ventures.
Shire's new CEO is consolidating R&D with the goal of broadening the company's reach in specialty pharma.
EMERGING COMPANY PROFILE
Galileo's allogeneic immunotherapy mimics natural killer cells, but they spare healthy cells and could have broader activity than off-the-shelf cancer vaccines in development.
With fresh EUR 60 million from its pharma parent, MS Ventures aims to take an active role in its portfolio companies and expand from its early stage focus into selected later-stage opportunities.
Elan is betting its shareholders will like the return from investing $1 billion for a slice of Theravance's royalties, but Theravance shareholders signaled they liked the cash better.
PeptiDreams of an IPO in Japan. Amgen, Novartis: Partners less limited at Atlas. Vivus-First Manhattan. Also: Gilead-Infinity; Halozyme; Oncothyreon; Tesaro; Acadia; Aegerion; Ambit; Lexicon; Optimer, et al.